Survey Based Discrete Choice Experiment Study in Prostate Cancer (DECIDER) Study

Astellas

Status: Completed

Conditions: Metastatic Hormone-sensitive Prostate Cancer; Prostate Cancer

Study type: Observational

Funder types: Industry

Identifiers

NCT05381311

9785-MA-3277

Details and patient eligibility

About

The purpose of this study is to quantify and publish participants' relative preferences for outcomes of chemotherapy and novel oral hormonal agents when added to androgen deprivation therapy (ADT) for participants with locally-advanced and metastatic hormone-sensitive prostate cancer (mHSPC). This study will also quantify the importance of administration factors related to convenience relative to treatment outcomes.

Full description

The study will develop and administer a discrete-choice experiment (DCE) to quantify tradeoff preferences of participants with mHSPC and locally-advanced prostate cancer in various countries. Data/surveys are being collected in: United States, Canada, UK, France, Spain, Japan, China and South Korea.

Enrollment: 1,020 patients

Sex: Male

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

For interviews (attribute prioritization and pretest interviews)

• Diagnosis of mHSPC with or without previous experience with ADT
• Able to read and understand the survey language
• Able to provide informed consent For online survey
• Diagnosis of mHSPC or locally-advanced prostate cancer with or without previous experience with ADT
• Able to read and understand the survey language
• Able to provide informed consent

Exclusion criteria

Not applicable